Burn Degree Second

4

Review clinical trials related to Burn Degree Second. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

The Use of Cultured (Dermal) Epithelial Autografts in Severely Burned Patients

The Swisskera project is a multicenter follow-up study at the three Swiss burn centers evaluating long-term outcomes after burn wound coverage with lab-grown epithelial grafts, specifically cultured epithelial autograft (CEA) and, where applicable, cultured dermal-epidermal autograft (CDEA). Patients who received CEA/CDEA between 1985 and 2023 will be invited for a study visit , using available clinical records and standardized long-term scar and skin assessments. Long-term skin quality will be evaluated by comparing the previously transplanted area with a matched healthy skin reference site using non-invasive measurements (e.g., thickness, transepidermal water loss, hydration, elasticity, and color). Optional small punch biopsies may be obtained from transplanted areas (under local anesthesia or during clinically indicated anesthesia) for histological and immunohistochemical characterization of scar tissue remodeling, including collagen and elastin architecture, vascularization, nerve fiber ingrowth, inflammatory cell patterns, and melanocyte distribution.

Participants needed: 236
Trial details
Biological sex: AllType: ObservationalSponsor: University Children's Hospital, ZurichUpdated: May 26, 2026Locations: 3
Eligibility criteria

Patients who have undergone treatment at the three Swiss burn centres and receiv... [+2]

Refusal of participation in the study by the patient or his/her legal representa... [+1]

Status: Recruiting

Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to Autografting

To evaluate the safety and efficacy of realSKIN® to provide complete wound closure of mixed-depth, full-thickness burn wounds as an alternative treatment to autografting.

Participants needed: 50
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: XenoTherapeutics, Inc.Updated: Apr 2, 2025Locations: 4
Eligibility criteria

The subject, or the subject's legally authorized representative (LAR), provides... [+10]

Pregnant or lactating women [+18]

Status: Not yet recruiting

A Study to Evaluate the Safety, Tolerability and Efficacy in Patients With Burn(s)

For Phase 1, researchers will explore the safety, and tolerability of PMS-101 and determine the recommended Phase 2 dose (RP2D) using the donor site. For Phase 2a, researchers will compare PMS-101 to a standard-of-care to see if PMS-101 works to treat mid-dermal burns.

Participants needed: 40
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Primoris TherapeuticsUpdated: Jul 5, 2024Locations: 1
Eligibility criteria

The combined TBSA of all burns is 10% or less. [+5]

Those who are allergic to or have experienced hypersensitivity to any components... [+25]